OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Substance Abuse Treatment is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
C2: editorial board	113
JSAT call for papers for special issue: Stimulant use disorder	98
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study	83
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids	80
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?	68
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail	59
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support	53
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings	53
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder	49
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up	48
Integrating substance use care into primary care for adolescents and young adults: Lessons learned	47
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts	47
Perspectives on electronic portal use among patients treated with medications for opioid use disorder in primary care	45
Clinical symptoms and personality traits predict subpopulations of treatment-seeking substance users	44
C2: editorial board	42
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders	40
The new services that opioid treatment programs have adopted in response to COVID-19	40
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data	39
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail	39
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services	39
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis	38
C2: editorial board	37
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments	37
Education and careers were our way out	36
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration	32

Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation	32
Suicide safer care in behavioral health settings: A comparative analysis of perceptions, training completion, and practice between mental health and substance use disorder treatment providers	31
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)	30
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study	30
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	30